Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Income from Continuing Operations: 2022-2025

Historic Income from Continuing Operations for ARS Pharmaceuticals (SPRY) over the last 4 years, with Sep 2025 value amounting to -$53.2 million.

  • ARS Pharmaceuticals' Income from Continuing Operations fell 144.58% to -$53.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$90.8 million, marking a year-over-year decrease of 50.04%. This contributed to the annual value of $8.0 million for FY2024, which is 114.71% up from last year.
  • According to the latest figures from Q3 2025, ARS Pharmaceuticals' Income from Continuing Operations is -$53.2 million, which was down 11.72% from -$47.6 million recorded in Q2 2025.
  • Over the past 5 years, ARS Pharmaceuticals' Income from Continuing Operations peaked at $47.2 million during Q4 2024, and registered a low of -$53.2 million during Q3 2025.
  • Moreover, its 3-year median value for Income from Continuing Operations was -$18.7 million (2023), whereas its average is -$19.0 million.
  • In the last 5 years, ARS Pharmaceuticals' Income from Continuing Operations crashed by 224.76% in 2023 and then soared by 561.54% in 2024.
  • Over the past 4 years, ARS Pharmaceuticals' Income from Continuing Operations (Quarterly) stood at -$15.4 million in 2022, then surged by 33.78% to -$10.2 million in 2023, then soared by 561.54% to $47.2 million in 2024, then plummeted by 144.58% to -$53.2 million in 2025.
  • Its Income from Continuing Operations stands at -$53.2 million for Q3 2025, versus -$47.6 million for Q2 2025 and -$37.2 million for Q1 2025.